NeuroPace (NASDAQ:NPCE – Get Free Report) had its price objective reduced by analysts at HC Wainwright from $20.00 to $12.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price target points to a potential upside of 46.34% from the company’s current price.
A number of other brokerages have also recently commented on NPCE. Weiss Ratings cut shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a report on Tuesday, September 15th. JPMorgan Chase & Co. cut shares of NeuroPace from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $20.00 to $9.00 in a research note on Friday, November 13th. Wells Fargo & Company downgraded shares of NeuroPace from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $19.00 to $9.00 in a report on Friday, November 13th. Finally, Wall Street Zen lowered shares of NeuroPace from a “hold” rating to a “sell” rating in a research report on Saturday. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, NeuroPace has an average rating of “Hold” and an average price target of $13.11.
Check Out Our Latest Research Report on NeuroPace
NeuroPace Stock Up 2.9%
Insider Activity
In related news, CFO Patrick F. Williams purchased 11,891 shares of NeuroPace stock in a transaction that occurred on Tuesday, November 17th. The stock was purchased at an average price of $8.34 per share, for a total transaction of $99,170.94. Following the transaction, the chief financial officer directly owned 79,399 shares in the company, valued at approximately $662,187.66. This trade represents a 17.61% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joel Becker purchased 11,891 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The stock was bought at an average cost of $8.35 per share, for a total transaction of $99,289.85. Following the completion of the purchase, the chief executive officer directly owned 149,891 shares in the company, valued at $1,251,589.85. This represents a 8.62% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 19.20% of the stock is owned by company insiders.
Institutional Investors Weigh In On NeuroPace
Large investors have recently bought and sold shares of the company. Soleus Capital Management L.P. increased its position in shares of NeuroPace by 10.5% during the third quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company’s stock worth $44,280,000 after purchasing an additional 306,878 shares in the last quarter. Entropy Technologies LP acquired a new position in NeuroPace in the 3rd quarter valued at $146,000. Diversified Trust Co purchased a new position in NeuroPace in the 3rd quarter valued at $153,000. First Light Asset Management LLC lifted its holdings in NeuroPace by 16.3% in the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock valued at $45,464,000 after purchasing an additional 401,201 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in NeuroPace in the 2nd quarter valued at $322,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
Top NeuroPace Stories
Here are a few of the latest stories about NPCE:
- Neutral Sentiment: Brokerages’ reported average price target is $20.50, suggesting significant potential upside from the recent share level, though targets can change and are not guarantees. Brokerage price target report
- Negative Sentiment: Wolfe Research downgraded NPCE from “strong buy” to “hold,” while Wall Street Zen cut its rating to “sell.” These changes add to pressure on investor sentiment. Wall Street Zen rating report
- Negative Sentiment: Recent coverage cites a third-quarter miss, weak implant activity and execution and regulatory risks. HC Wainwright and Cantor Fitzgerald lowered their price targets to $12, although both retained bullish ratings. Zacks analysis
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Further Reading
- Five stocks we like better than NeuroPace
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
